Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1L1 | Q9UHC9 | 6/20 | 1.00 |
| ▸ | RORA | P35398 | 3/20 | 1.00 |
| ▸ | USP2 | O75604 | 3/20 | 1.00 |
| ▸ | MEN1 | O00255 | 2/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 2/20 | 1.00 |
| ▸ | ALOX15 | P16050 | 1/20 | 1.00 |
| ▸ | NR1H3 | Q13133 | 2/20 | 0.73 |
| ▸ | RORC | P51449 | 4/20 | 0.67 |
| ▸ | GPR183 | P32249 | 4/20 | 0.67 |
| ▸ | OSBP | P22059 | 3/20 | 0.67 |
| ▸ | LMNA | P02545 | 2/20 | 0.67 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.67 |
| ▸ | OSBP2 | Q969R2 | 1/20 | 0.67 |
| ▸ | CYP46A1 | Q9Y6A2 | 1/20 | 0.67 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.65 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.65 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.65 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.65 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.65 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| 7-Oxocholesterol SCHEMBL19866342 | 1.00 | NPC1L1 (1.00) | NPC1L1RORAUSP2MEN1KMT2A | |
| 7-Oxocholesterol SCHEMBL19545218 | 1.00 | NPC1L1 (1.00) | NPC1L1RORAUSP2MEN1KMT2A | |
| 7-Oxocholesterol SCHEMBL19545521 | 1.00 | NPC1L1 (1.00) | NPC1L1RORAUSP2MEN1KMT2A | |
| 7-Oxocholesterol SCHEMBL19858756 | 1.00 | NPC1L1 (1.00) | NPC1L1RORAUSP2MEN1KMT2A | |
| 7-Oxocholesterol SCHEMBL14629361 | 1.00 | NPC1L1 (1.00) | NPC1L1RORAUSP2MEN1KMT2A | |
| 7-Oxocholesterol SCHEMBL231535 | 1.00 | NPC1L1 (1.00) | NPC1L1RORAUSP2MEN1KMT2A | |
| 7-Oxocholesterol SCHEMBL23062985 | 1.00 | NPC1L1 (1.00) | NPC1L1RORAUSP2MEN1KMT2A | |
| 7-Oxocholesterol SCHEMBL6389039 | 1.00 | NPC1L1 (1.00) | NPC1L1RORAUSP2MEN1KMT2A | |
| 7-Oxocholesterol SCHEMBL2600410 | 1.00 | NPC1L1 (1.00) | NPC1L1RORAUSP2MEN1KMT2A | |
| 7-Oxocholesterol SCHEMBL22959498 | 1.00 | NPC1L1 (1.00) | NPC1L1RORAUSP2MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1264 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122055615-A | Method for diagnosing exposure of skin to ozone | 欧莱雅 | 2026-05-15 | — | — | CN | claimed |
| WO-2026090423-A1 | UNIVERSAL LNP COMPOSITIONS | PRIME MEDICINE, INC (US) | 2026-04-30 | — | — | WO | claimed |
| EP-4706644-A1 | RECONSTITUTED HIGH-DENSITY LIPOPROTEIN NANOPARTICLES COMPRISING CHOLESTEROL | Mepsgen Co., Ltd. (KR) | 2026-03-11 | — | — | EP | claimed |
| US-20250345358-A1 | HYDROXYPROPYL BETA-CYCLODEXTRIN COMPOSITIONS AND METHODS | MANDOS LLC (US) | 2025-11-13 | — | — | US | claimed |
| US-20250345284-A1 | LIPID NANOPARTICLE (LNP) COMPOSITIONS AND METHODS OF USE THEREOF | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2025-11-13 | — | — | US | claimed |
| US-20250326839-A1 | TREATMENT OF DISEASES RELATED TO COLONY-STIMULATING FACTOR 1 RECEPTOR DYSFUNCTION USING TREM2 AGONISTS | VIGIL NEUROSCIENCE INC (US) | 2025-10-23 | — | — | US | claimed |
| US-20250282866-A1 | TREATMENT OF DISEASES RELATED TO ATP-BINDING CASSETTE TRANSPORTER 1 DYSFUNCTION USING TREM2 AGONISTS | VIGIL NEUROSCIENCE INC (US) | 2025-09-11 | — | — | US | claimed |
| WO-2025132799-A1 | METHODS FOR DIAGNOSIS AND MONITORING NASH DISEASE | Institut National de la Santé et de la Recherche Médicale (FR) | 2025-06-26 | — | — | WO | claimed |
| CN-120084899-A | HPLC analysis method capable of simultaneously controlling two different 7-dehydrocholesterol synthesis routes | 苏州恩泰新材料科技有限公司 | 2025-06-03 | — | — | CN | claimed |
| WO-2025073784-A1 | METHOD FOR DIAGNOSING A SKIN EXPOSED TO OZONE | L'OREAL (FR) | 2025-04-10 | — | — | WO | claimed |
| US-20030139616-A1 | Method of searching for arteriosclerosis inhibitors and shrinkers | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2003-07-24 | — | — | US | claimed |
| WO-2001015676-A9 | COMPOSITIONS AND METHODS FOR MODULATING HDL CHOLESTEROL AND TRIGLYCERIDE LEVELS | UNIV BRITISH COLUMBIA (CA) | 2003-06-19 | — | — | WO | claimed |
| WO-2003049685-A2 | TREATMENT FOR AGE-RELATED MACULAR DEGENERATION | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2003-06-19 | — | — | WO | claimed |
| EP-1277760-A1 | METHOD OF SEARCHING FOR ARTERIOSCLEROSIS INHIBITORS AND SHRINKERS | Takeda Chemical Industries, Ltd. (JP) | 2003-01-22 | — | — | EP | claimed |
| EP-1239848-A2 | COMPOSITIONS AND METHODS FOR MODULATING HDL CHOLESTEROL AND TRIGLYCERIDE LEVELS | University of British Columbia (CA) | 2002-09-18 | — | — | EP | claimed |
| WO-2002043742-A1 | CYCLODEXTRINS AND REVERSAL OF ATHEROSCLEROSIS | THE HEART RESEARCH INSTITUTE LTD (AU) | 2002-06-06 | — | — | WO | claimed |
| WO-2001015676-A2 | COMPOSITIONS AND METHODS FOR MODULATING HDL CHOLESTEROL AND TRIGLYCERIDE LEVELS | UNIVERSITY OF BRITISH COLUMBIA (CA) | 2001-03-08 | — | — | WO | claimed |
| WO-1999024400-A1 | PROBUCOL ESTERS AND USES THEREOF | VYREX CORPORATION (US) | 1999-05-20 | — | — | WO | claimed |
| US-4304726-A | REDUCING 7-KETOCHOLESTEROL HALFESTER WITH COMPLEX METAL HYDRIDE | THE GREEN CROSS CORPORATION (JP) | 1981-12-08 | — | — | US | claimed |
| US-4157391-A | IMMUNOREGULATORY AGENTS OR ANTIPHLOGISTIC AGENTS | THE GREEN CROSS CORPORATION (JP) | 1979-06-05 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250345284-A1 | LIPID NANOPARTICLE (LNP) COMPOSITIONS AND METHODS OF USE THEREOF | CD47, CETP, HAVCR2 | NPC1L1 18/4885RORA 26/4885USP2 4200/4885 |
| US-20250345358-A1 | HYDROXYPROPYL BETA-CYCLODEXTRIN COMPOSITIONS AND METHODS | GBA1, NPC1, GBA2 | NPC1L1 6/4885RORA 1463/4885USP2 1973/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.